CI-988: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
== CI-988 == | |||
[[File:CI-988_structure.png|thumb|right|Chemical structure of CI-988]] | |||
CI-988 | |||
'''CI-988''' is a [[pharmacological]] compound that acts as a selective antagonist of the [[cholecystokinin]] (CCK) receptor, specifically the CCK<sub>A</sub> receptor subtype. It has been studied for its potential therapeutic applications in various [[neurological]] and [[psychiatric]] disorders. | |||
CI-988 | |||
== | == Mechanism of Action == | ||
CI-988 functions by inhibiting the action of the [[neurotransmitter]] cholecystokinin at the CCK<sub>A</sub> receptors. These receptors are primarily located in the [[gastrointestinal tract]] and the [[central nervous system]]. By blocking these receptors, CI-988 can modulate the effects of cholecystokinin, which is involved in processes such as [[anxiety]], [[pain perception]], and [[appetite regulation]]. | |||
== Potential Therapeutic Uses == | |||
=== Anxiety Disorders === | |||
CI-988 has been investigated for its potential use in treating [[anxiety disorders]]. The blockade of CCK<sub>A</sub> receptors may reduce anxiety symptoms, as cholecystokinin is known to play a role in the modulation of anxiety. | |||
=== Pain Management === | |||
The compound has also been studied for its analgesic properties. By antagonizing CCK<sub>A</sub> receptors, CI-988 may enhance the effects of [[opioid]]s and reduce pain perception, offering a potential adjunctive treatment in pain management. | |||
=== Appetite Regulation === | |||
Cholecystokinin is involved in the regulation of [[appetite]] and [[satiety]]. CI-988's action on CCK<sub>A</sub> receptors suggests it could influence eating behaviors and potentially be used in the treatment of [[obesity]] or [[eating disorders]]. | |||
== Pharmacokinetics == | |||
CI-988 is administered orally and undergoes [[metabolism]] in the [[liver]]. Its pharmacokinetic profile includes a moderate half-life, allowing for potential therapeutic use with manageable dosing schedules. | |||
== Research and Development == | |||
Research on CI-988 has primarily been conducted in [[preclinical]] and early [[clinical trials]]. While results have shown promise, further studies are needed to fully understand its efficacy and safety profile in humans. | |||
== Related Pages == | |||
* [[Cholecystokinin]] | * [[Cholecystokinin]] | ||
* [[ | * [[Receptor antagonist]] | ||
* [[ | * [[Anxiety disorder]] | ||
* [[ | * [[Pain management]] | ||
* [[ | * [[Appetite regulation]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category: | [[Category:Receptor antagonists]] | ||
[[Category: | [[Category:Experimental drugs]] | ||
Latest revision as of 03:45, 13 February 2025
CI-988[edit]
CI-988 is a pharmacological compound that acts as a selective antagonist of the cholecystokinin (CCK) receptor, specifically the CCKA receptor subtype. It has been studied for its potential therapeutic applications in various neurological and psychiatric disorders.
Mechanism of Action[edit]
CI-988 functions by inhibiting the action of the neurotransmitter cholecystokinin at the CCKA receptors. These receptors are primarily located in the gastrointestinal tract and the central nervous system. By blocking these receptors, CI-988 can modulate the effects of cholecystokinin, which is involved in processes such as anxiety, pain perception, and appetite regulation.
Potential Therapeutic Uses[edit]
Anxiety Disorders[edit]
CI-988 has been investigated for its potential use in treating anxiety disorders. The blockade of CCKA receptors may reduce anxiety symptoms, as cholecystokinin is known to play a role in the modulation of anxiety.
Pain Management[edit]
The compound has also been studied for its analgesic properties. By antagonizing CCKA receptors, CI-988 may enhance the effects of opioids and reduce pain perception, offering a potential adjunctive treatment in pain management.
Appetite Regulation[edit]
Cholecystokinin is involved in the regulation of appetite and satiety. CI-988's action on CCKA receptors suggests it could influence eating behaviors and potentially be used in the treatment of obesity or eating disorders.
Pharmacokinetics[edit]
CI-988 is administered orally and undergoes metabolism in the liver. Its pharmacokinetic profile includes a moderate half-life, allowing for potential therapeutic use with manageable dosing schedules.
Research and Development[edit]
Research on CI-988 has primarily been conducted in preclinical and early clinical trials. While results have shown promise, further studies are needed to fully understand its efficacy and safety profile in humans.
